<DOC>
	<DOCNO>NCT00850239</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy dutogliptin 26 week ( evidence placebo-corrected change HbA1c relative baseline ) , demonstrate safety tolerability dutogliptin , demonstrate change fast plasma glucose 26 week .</brief_summary>
	<brief_title>Safety Efficacy Study Dutogliptin/PHX1149T Subjects With Type 2 Diabetes Mellitus Background Medication Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus , diagnose least 4 month prior Screening ( Visit 1 ) Age 18 85 year , inclusive . Male nonpregnant , nonlactating ( plan become pregnant study ) female subject BMI 20 48 kg/m2 , inclusive Current treatment Type 2 diabetes mellitus stable dose metformin â‰¥ 2000 mg ( high tolerate dose ) use accordance product label least 6 week prior screen ( Visit 1 ) HbA1c 7.0 % 10.0 % , inclusive ; fast plasma C peptide great 0.26 nmol/L ( &gt; 0.8 ng/mL ; &gt; 281 pmol/L ) screening ( Visit 1 ) Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>diabetes</keyword>
	<keyword>DPP4 inhibitor</keyword>
	<keyword>dutogliptin</keyword>
</DOC>